| Cobalt Blue Holdings Limited (COB) ORDINARY FULLY PAID |
Materials |
$25 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
24 Jul 2024 9:13AM |
$0.081 |
$0.056 |
fallen by
30.86%
|
|
COB - Price-sensitive ASX Announcement
Full Release
Key Points
- Refinery development program ongoing with feedstock testing.
- Discussions with potential feedstock suppliers adhering to environmental and labor standards.
- Broken Hill Cobalt Project under review for optimal mining/development options.
- Exploring re-mining opportunities, including a cooperation agreement with Hudbay Minerals Inc.
- Reported cash and cash equivalents of $8.742 million at the end of the quarter.
- Quarterly expenditures on exploration, development, and related activities outlined.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$37 |
Update - Notification of buy-back - MEC
|
24 Jul 2024 9:13AM |
$0.990 |
$1.060 |
risen by
7.07%
|
|
| Metallica Minerals Limited (MLM) ORDINARY FULLY PAID |
Materials |
- |
Change in substantial holding
|
24 Jul 2024 9:13AM |
$0.030 |
$0.034 |
risen by
13.33%
|
|
| Beonic Ltd (BEO) ORDINARY FULLY PAID |
Information Technology |
$14 |
Notice of Extraordinary General Meeting/Proxy Form
|
24 Jul 2024 9:11AM |
$0.032 |
$0.200 |
risen by
525%
|
|
| Incitec Pivot Limited (IPL) ORDINARY FULLY PAID |
Materials |
$4,827 |
Update - Notification of buy-back - IPL
|
24 Jul 2024 9:10AM |
$2.850 |
$2.590 |
fallen by
9.12%
|
|
| Diatreme Resources Limited (DRX) ORDINARY FULLY PAID |
Materials |
$100 |
Change in substantial holding for MLM
|
24 Jul 2024 9:09AM |
$0.027 |
$0.020 |
fallen by
25.93%
|
|
| Metallica Minerals Limited (MLM) ORDINARY FULLY PAID |
Materials |
- |
Change in substantial holding from DRX
|
24 Jul 2024 9:09AM |
$0.030 |
$0.034 |
risen by
13.33%
|
|
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$36 |
Investor Presentation
|
24 Jul 2024 9:09AM |
$0.900 |
$0.325 |
fallen by
63.89%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma is commercialising SPONTAN®, a 'First in Class' rapid, on-demand nasal spray for erectile dysfunction.
- Pivotal pharmacokinetic study demonstrated SPONTAN's rapid onset and consistent delivery.
- Targeting expedited regulatory approval in the US and Australia within 1-2 years.
- Exploring partnership and licensing opportunities with large pharmaceutical companies.
- Focused on leveraging online sales channels post-regulatory approval.
- Capital raise of A$10.5 million to fund sales and marketing, regulatory studies, and R&D pipeline expansion.
- Key milestones include release of full pivotal clinical trial data and regulatory pre-submission meetings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$36 |
Proposed issue of securities - LTP
|
24 Jul 2024 9:09AM |
$0.900 |
$0.325 |
fallen by
63.89%
|
|
| Trinex Minerals Limited (TX3) ORDINARY FULLY PAID |
Materials |
$2 |
VTEM Identifies Numerous Conductors at Gibbons Creek Uranium
|
24 Jul 2024 9:09AM |
$0.003 |
$0.001 |
fallen by
66.67%
|
|
TX3 - Price-sensitive ASX Announcement
Full Release
Key Points
- Preliminary VTEM data identifies numerous conductors at the Gibbons Creek Uranium Project.
- Conductor trends show breaks associated with cross-cutting structures, presenting drilling targets.
- Further processing and modeling work expected to complete in August.
- Planned drilling at Airstrip and Butler Lake Prospects during Canadian summer field season.
- Trinex Minerals holds an option to earn up to a 75% interest in the Gibbons Creek Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| LTR Pharma Ltd (LTP) ORDINARY FULLY PAID |
Health Care |
$36 |
LTR Pharma completes A$10.5 million placement
|
24 Jul 2024 9:09AM |
$0.900 |
$0.325 |
fallen by
63.89%
|
|
LTP - Price-sensitive ASX Announcement
Full Release
Key Points
- LTR Pharma successfully raised A$10.5 million through a Share Placement.
- The placement was in high demand and exceeded the A$10.5 million raised.
- Funds will be used to advance SPONTAN®'s regulatory pathways, expand R&D, and bolster marketing.
- LTR Pharma aims to expedite the commercialisation of SPONTAN®.
- SPONTAN® is an innovative nasal spray treatment for Erectile Dysfunction.
- The placement was made at A$0.73 per share, a 13.2% discount to the 30-day VWAP.
- Settlement of the placement is expected on 30 July 2024.
- Alpine Capital Pty Ltd acted as the Sole Lead Manager for the placement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| US Masters Residential Property Fund (URF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$263 |
Update - Notification of buy-back - URF
|
24 Jul 2024 9:07AM |
$0.290 |
$0.380 |
risen by
31.03%
|
|
| NAOS Small Cap Opportunities Company Limited (NSC) ORDINARY FULLY PAID |
Financials |
$40 |
NAOS Quarterly Investment Report - Q4 FY24
|
24 Jul 2024 9:06AM |
$0.465 |
$0.295 |
fallen by
36.56%
|
|
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$21 |
NAOS Quarterly Investment Report - Q4 FY24
|
24 Jul 2024 9:06AM |
$0.480 |
$0.440 |
fallen by
8.33%
|
|
| Naos Emerging Opportunities Company Limited (NCC) ORDINARY FULLY PAID |
Financials |
$22 |
NAOS Quarterly Investment Report - Q4 FY24
|
24 Jul 2024 9:05AM |
$0.445 |
$0.300 |
fallen by
32.58%
|
|
| Atrum Coal Limited (ATU) ORDINARY FULLY PAID |
Materials |
$21 |
Quarterly Activities Report
|
24 Jul 2024 9:05AM |
$0.005 |
$0.005 |
fallen by
0%
|
|
| Coast Entertainment Holdings Limited (CEH) ORDINARY FULLY PAID |
Consumer Discretionary |
$175 |
Update - Notification of buy-back - CEH
|
24 Jul 2024 9:05AM |
$0.490 |
$0.405 |
fallen by
17.35%
|
|
| Trigg Minerals Limited (TMG) ORDINARY FULLY PAID |
Materials |
$57 |
Board Changes
|
24 Jul 2024 9:05AM |
$0.010 |
$0.062 |
risen by
520%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,618 |
Appendix 3B
|
24 Jul 2024 9:04AM |
$20.310 |
$25.490 |
risen by
25.50%
|
|
| Atrum Coal Limited (ATU) ORDINARY FULLY PAID |
Materials |
$21 |
Quarterly Appendix 5B Cash Flow Report
|
24 Jul 2024 9:03AM |
$0.005 |
$0.005 |
fallen by
0%
|
|
| Jervois Global Limited (JRV) ORDINARY FULLY PAID |
Materials |
$30 |
Jervois presents at U.S. House Select Committee roundtable
|
24 Jul 2024 9:03AM |
$0.019 |
$0.011 |
fallen by
42.11%
|
|
| PharmAust Limited (PAA) ORDINARY FULLY PAID |
Health Care |
- |
PharmAust Completes Share Purchase Plan
|
24 Jul 2024 9:02AM |
$0.210 |
$0.230 |
risen by
9.52%
|
|
PAA - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful completion of Share Purchase Plan (SPP) raising $7.8m
- Demand was significantly in excess of the initial $2m sought
- $17.8m in combined proceeds from the SPP and Placement significantly reduces future funding requirements to execute the HEALEY ALS Platform Trial
- Exceptional support from shareholders on the same terms as the recently completed $10m institutional and sophisticated investor Placement
- Potential additional nondilutive funds from R&D Tax Incentive and grants in H2 CY2024
- A total of 41,095,506 new fully paid ordinary shares will be issued on 25 July 2024, to SPP participants
- Funds raised under the SPP will be used to finalise preparations for the HEALEY ALS Platform Trial, GMP manufacturing, preclinical models for other neurodegenerative diseases, regulatory filings, working capital and offer costs
- The SPP complements the Company’s recently announced placement to institutional and sophisticated investors, which raised $10 million
- PharmAust is well-positioned to finalise preparations towards commencing a pivotal registration study for monepantel for the treatment of amyotrophic lateral sclerosis
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Panoramic Resources Limited (PAN) ORDINARY FULLY PAID |
Materials |
- |
Second Creditors Meeting called by Administrators
|
24 Jul 2024 9:02AM |
$0.035 |
$0.035 |
fallen by
0%
|
|
| Rox Resources Limited (RXL) ORDINARY FULLY PAID |
Materials |
$223 |
Youanmi Gold Project - Positive Pre-Feasibility Study
|
24 Jul 2024 9:02AM |
$0.145 |
$0.305 |
risen by
110.34%
|
|
RXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Average annual gold production target of ~103koz per annum.
- The average gold head grade is 4.5g/t Au.
- Total gold doré produced is approximately 786koz over the life-of-mine.
- Compelling financial forecasts at a conservative gold price of A$3,100/oz.
- Project life is approximately 7.7 years with a cumulative EBITDA of approximately $1,219m.
- Pre-tax undiscounted free cash flow of approximately $855m and $597m post-tax.
- Pre-tax and unleveraged Net Present Value (NPV8) of approximately $486m and $322m post-tax.
- Pre-tax and unleveraged Internal Rate of Return (IRR) of approximately 42% and 33% post-tax.
- LOM All-In Sustaining Cost (AISC) average forecast of A$1,676/oz.
- The project is viable on technical, economic, environmental, and social bases.
- Recommendations include the commencement of further technical studies and approvals documentation.
- Total pre-production capital expenditure of approximately $245m.
- Financial forecasts at a spot gold price of A$3,500/oz demonstrate significant upside.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Limited (PPT) ORDINARY FULLY PAID |
Financials |
$2,053 |
Fourth Quarter FY24 Business Update
|
24 Jul 2024 9:01AM |
$22.750 |
$17.910 |
fallen by
21.27%
|
|
PPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Perpetual Limited released its fourth quarter FY24 business update for the period ending 30 June 2024.
- The company experienced mixed performance across its divisions.
- Corporate Trust and Wealth Management showed steady performance.
- Asset Management saw net outflows and was impacted by market and currency movements.
- Total Assets Under Management (AUM) for Asset Management were A$215.0 billion as of 30 June 2024.
- Wealth Management’s total Funds Under Administration (FUA) was A$19.8 billion as of 30 June 2024.
- The Debt Market Services (DMS) division reported FUA of A$711 billion and the Managed Funds Services (MFS) division reported FUA of A$496 billion.
- Integration of Pendal Group remains ahead of plan with targeted synergies of A$80 million.
- A Scheme of Arrangement with KKR is underway for the sale of Wealth Management and Corporate Trust businesses.
- Expense growth for FY24 is expected to be at the lower end of the 32%-34% guidance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
